Clinical Trial Update: LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

View source ↗

Summary

A post-marketing surveillance study for olaparib (LYNPARZA) in pancreatic cancer in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Pancreatic Neoplasms | Status: COMPLETED